Needham Maintains Buy on RxSight, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Needham analyst David Saxon maintains a Buy rating on RxSight (NASDAQ:RXST) and raises the price target from $54 to $66.
August 20, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst David Saxon has reaffirmed a Buy rating for RxSight and increased the price target from $54 to $66, indicating a positive outlook for the stock.
The increase in the price target from $54 to $66 by a reputable analyst suggests a positive outlook for RxSight, likely leading to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100